Skip to content
Screener

LivaNova LIVN Cardiopulmonary — Net revenue

Other segment segments

Neuromodulation
$166.95M+10.1%

Similar metrics at other companies

Installed Building Products logo
IBPNet revenue, Installation — Net revenue
$710.7M-0.7%
Marqeta logo
MQPlatform services revenue, net — Net revenue
$156.23M+18.5%
Visa logo
VOther revenue — Net revenue
$1.5B+45.5%
Visa logo
VService revenue — Net revenue
$4.92B+13.7%
Cavco Industries logo
CVCODelivery, setup and other revenues — Net revenue
$23.21M-15.9%
Advanced Micro Devices logo
AMDDatacenter — Net revenue
$10.25B+37.8%

Other financials

Income statement

See full
Revenue$390.6M+10.8%
Gross profit$273.7M+14.5%
Operating income$49.5M-8.7%
Net income$108.6M+300%
EPS (diluted)$1.93+286%

Balance sheet

See full
Cash & equivalents$516.6M-13.0%
Total debt$348.5M-27.8%
Total equity$1.3B+18.0%
Total assets$2.6B+5.4%

Cash flow

See full
Operating cash flow$66.6M+5.8%
CapEx$31.6M+108%
Free cash flow$35.0M-26.7%

Valuation

See full
Market cap$4.17B+61.5%
Enterprise value$4.01B+61.9%
P/E22.6×-67.9×
P/S2.8×+0.9×

Profitability

See full
Gross margin68.1%+0.1pp
Operating margin12.7%-0.7pp
Net margin-16.1%-18.0pp
FCF margin10.1%-2.3pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.2×
Current ratio1.4×+0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: LivaNova’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 2:23 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001639691-26-000090
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
United States$72,793$71,243$142,072$132,077
Europe (1)61,95949,046119,26393,553
Rest of World (1)86,82478,983168,896149,962
221,576199,272430,231375,592
Neuromodulation
United States126,556117,226241,956225,560
Europe (1)19,85817,73038,20632,924
Rest of World (1)20,53116,71438,57132,079

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is LivaNova's cardiopulmonary — net revenue?
LivaNova (LIVN) reported cardiopulmonary — net revenue of $221.58M in Q2 2026.
How has LivaNova's cardiopulmonary — net revenue changed year-over-year?
LivaNova's cardiopulmonary — net revenue increased by 11.2% year-over-year, from $199.27M to $221.58M.
What is the long-term trend for LivaNova's cardiopulmonary — net revenue?
Over 4 years (2021 to 2025), LivaNova's cardiopulmonary — net revenue has grown at a 12.9% compound annual growth rate (CAGR), from $482.98M to $785.39M.
What does cardiopulmonary — net revenue mean?
Represents the total gross sales generated by the cardiopulmonary business segment after deducting returns, allowances, and discounts. This metric serves as a primary indicator of the segment's market demand and top-line growth performance.

Ask your AI about LivaNova's cardiopulmonary — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude